MA34007B1 - Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation - Google Patents

Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation

Info

Publication number
MA34007B1
MA34007B1 MA35152A MA35152A MA34007B1 MA 34007 B1 MA34007 B1 MA 34007B1 MA 35152 A MA35152 A MA 35152A MA 35152 A MA35152 A MA 35152A MA 34007 B1 MA34007 B1 MA 34007B1
Authority
MA
Morocco
Prior art keywords
compounds
preparation
pyridine derivatives
drugs containing
tricyclic pyridine
Prior art date
Application number
MA35152A
Other languages
Arabic (ar)
English (en)
Inventor
Klaus Fuchs
Holger Wagner
Daniela Berta
Riccardo Giovannini
Dieter Wolfgang Hamprecht
Ingo Konetzki
Ruediger Streicher
Thomas Trieselmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA34007B1 publication Critical patent/MA34007B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS DE FORMULE I DANS LAQUELLE LES VARIABLES R1 À R8 SONT TELLES QUE DÉFINIES DANS LA DESCRIPTION, LESDITS COMPOSÉS POSSÉDANT UNE ACTIVITÉ PHARMACOLOGIQUE INTÉRESSANTE. CES COMPOSÉS CONSTITUENT NOTAMMENT DES INHIBITEURS DE LA PROTÉINE DE TRANSFERT DU CHOLESTÉROL ESTÉRIFIÉ (CETP) ET PEUVENT DONC ÊTRE UTILISÉS POUR LE TRAITEMENT ET LA PRÉVENTION DE MALADIES POUVANT ÊTRE INFLUENCÉES DE L'INHIBITION DE LADITE ENZYME.
MA35152A 2010-02-19 2011-02-17 Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation MA34007B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10154086 2010-02-19
PCT/EP2011/052376 WO2011101424A1 (fr) 2010-02-19 2011-02-17 Dérivés tricycliques de pyridine, médicaments contenant lesdits composés, utilisation associée et procédé de préparation associée

Publications (1)

Publication Number Publication Date
MA34007B1 true MA34007B1 (fr) 2013-02-01

Family

ID=43877277

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35152A MA34007B1 (fr) 2010-02-19 2011-02-17 Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation

Country Status (22)

Country Link
US (2) US20120053197A1 (fr)
EP (1) EP2536733B1 (fr)
JP (1) JP5780528B2 (fr)
KR (1) KR20130000379A (fr)
CN (1) CN102869667A (fr)
AP (1) AP2012006390A0 (fr)
AR (1) AR080228A1 (fr)
AU (1) AU2011217206A1 (fr)
BR (1) BR112012020591A2 (fr)
CA (1) CA2790643A1 (fr)
CL (1) CL2012002035A1 (fr)
CO (1) CO6592112A2 (fr)
EA (1) EA201201160A1 (fr)
EC (1) ECSP12012157A (fr)
MA (1) MA34007B1 (fr)
MX (1) MX2012009149A (fr)
PE (1) PE20121743A1 (fr)
SG (1) SG183321A1 (fr)
TN (1) TN2012000418A1 (fr)
TW (1) TW201139445A (fr)
UY (1) UY33229A (fr)
WO (1) WO2011101424A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2268644T3 (pl) * 2008-03-05 2012-01-31 Boehringer Ingelheim Int Tricykliczne pochodne piperydyny, leki zawierające te związki, ich zastosowanie i sposoby ich wytwarzania
US20120053197A1 (en) 2010-02-19 2012-03-01 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
US20130053404A1 (en) * 2011-02-17 2013-02-28 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
US9150583B2 (en) 2011-08-17 2015-10-06 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
US20130210851A1 (en) * 2011-08-18 2013-08-15 Boehringer Ingelheim International Gmbh Crystalline forms of a hexahydrofuro[3,4-c]quinoline derivative
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
CN103882766B (zh) * 2014-03-21 2015-10-28 湖南中烟工业有限责任公司 一种除去包装卡纸中酮类物质的除酮添加剂及其应用
CN103866646B (zh) * 2014-03-21 2015-10-28 湖南中烟工业有限责任公司 一种生产无酮转移卡纸的工艺

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798619A (en) 1980-06-02 1989-01-17 American Cyanamid Co. 2-(2-imidazolin-2-yl)-pyridines and quinolines and use of said compounds as herbicidal agents
US4475407A (en) 1982-12-27 1984-10-09 Brunswick Corporation Temperature compensated flow sensor
CH664578A5 (de) * 1985-01-15 1988-03-15 Ciba Geigy Ag Ringsubstituierte 4-azaphthalide.
JPH04500506A (ja) 1988-08-16 1992-01-30 ジ・アップジョン・カンパニー Ａｃａｔ酵素をブロックするのに有効な二価リガンド類
AP876A (en) 1995-09-29 2000-09-27 Glaxo Wellcome Spa Tetrahydroquinolines as NMDA antagonists.
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
HUP0004935A3 (en) 1997-09-04 2001-12-28 Basf Ag Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
JP3955180B2 (ja) 1998-09-25 2007-08-08 ファルマシア・コーポレーション コレステリルエステル伝達タンパク質活性を阻害するのに有用な（Ｒ）−キラルなハロゲン化された１−置換アミノ−（ｎ＋１）−アルカノール
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6479552B2 (en) 1999-09-23 2002-11-12 G.D. Searle & Co. Use of substituted N, N-disubstituted diamino compounds for inhibiting cholesteryl ester transfer protein activity
US6683113B2 (en) 1999-09-23 2004-01-27 Pharmacia Corporation (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10238243A1 (de) * 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AU2005233160B2 (en) 2004-04-13 2011-06-02 Merck Sharp & Dohme Corp. CETP inhibitors
PE20060653A1 (es) 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1
DE102004060997A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Chemische Verbindung und ihre Verwendung
AU2005315770B2 (en) 2004-12-18 2011-12-08 Bayer Schering Pharma Aktiengesellschaft 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
BRPI0519566A2 (pt) 2004-12-18 2009-01-27 Bayer Healthcare Ag derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp
JP2008201760A (ja) * 2007-02-22 2008-09-04 Tokyo Univ Of Agriculture & Technology 光学活性スピロ化合物及びその製造方法
PL2268644T3 (pl) * 2008-03-05 2012-01-31 Boehringer Ingelheim Int Tricykliczne pochodne piperydyny, leki zawierające te związki, ich zastosowanie i sposoby ich wytwarzania
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
US20120053197A1 (en) 2010-02-19 2012-03-01 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
US20130053404A1 (en) 2011-02-17 2013-02-28 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
US9150583B2 (en) 2011-08-17 2015-10-06 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
US20130210851A1 (en) 2011-08-18 2013-08-15 Boehringer Ingelheim International Gmbh Crystalline forms of a hexahydrofuro[3,4-c]quinoline derivative

Also Published As

Publication number Publication date
EP2536733B1 (fr) 2014-11-26
AP2012006390A0 (en) 2012-08-31
US20120053197A1 (en) 2012-03-01
KR20130000379A (ko) 2013-01-02
AU2011217206A1 (en) 2012-08-02
CA2790643A1 (fr) 2011-08-25
SG183321A1 (en) 2012-09-27
EA201201160A1 (ru) 2013-04-30
CO6592112A2 (es) 2013-01-02
TN2012000418A1 (en) 2014-01-30
EP2536733A1 (fr) 2012-12-26
CL2012002035A1 (es) 2013-02-01
CN102869667A (zh) 2013-01-09
JP2013519709A (ja) 2013-05-30
AR080228A1 (es) 2012-03-21
US20120046304A1 (en) 2012-02-23
JP5780528B2 (ja) 2015-09-16
US9029544B2 (en) 2015-05-12
WO2011101424A1 (fr) 2011-08-25
ECSP12012157A (es) 2012-10-30
PE20121743A1 (es) 2012-12-22
UY33229A (es) 2011-09-30
TW201139445A (en) 2011-11-16
MX2012009149A (es) 2012-09-28
BR112012020591A2 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
MA34007B1 (fr) Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
EA201270780A1 (ru) С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич
SG10201909545XA (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
BR112013026834A2 (pt) composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
WO2014031928A3 (fr) Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
IN2015DN01151A (fr)
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
WO2012104007A3 (fr) Dérivés de 7-azaindole
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201490545A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ С-Kit
MY163202A (en) Indolizine derivatives, proces for the preparation thereof and therapeutic use thereof
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
WO2014031933A3 (fr) Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
WO2014031936A3 (fr) Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
MX2016005437A (es) Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3 -carboxamida como inhibidores de glucosilceramida sintasa.
WO2012078519A3 (fr) Dérivés 3-acylidène-2-oxoindole destinés à inhiber la transglutaminase 2
EA201391820A1 (ru) Гетероциклические сульфонамидные производные
MY164138A (en) Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
WO2012019428A8 (fr) Dérivés de benzohydrol, procédé de préparation et utilisation pharmaceutique de ceux-ci